Estimated proportions of locally advanced cervical cancer by patient age
| Reference | Region | Location/data collection period | Age group, years | N | Percent with locally advanced cervical cancer (total) | Percent with locally advanced cervical cancer (by stage) |
| Studies of older women with cervical cancer | ||||||
| McLean et al4 2012 | North America | USA 1992–2007 | ≥70, Medicare enrolled | 734 | 44.4% | II, 20.8% III, 23.6% |
| Garry et al10 2018 | Europe | Ireland Dublin 2006–2015 | ≥60 | 119 | 49.0% | II, 28.0% III, 21.0% |
| Studies of young women with cervical cancer | ||||||
| Popadiuk et al12 2010 | North America | Canada Newfoundland 1992–2008 | 19–29 | 37 | 13.9% | IIB, 9.3% IIIB, 2.3% IVA, 2.3% |
| Litvinova et al14 2017 | Europe | Belarus Minsk City 2012–2016 | Young women | 94 | 100% | IIB, 45.7% III, 52.2% IVA, 2.1% |
| Nathani et al13 2012 | Europe | UK Bradford 2007–2011 | 19–30 | 19 | 5.3% | III, 5.3% |
| Studies reporting proportions of age groups by stage of cervical cancer | ||||||
| Tian et al*9 2020 | North America | USA 2010–2015 | Squamous cell <40 40–49 50–59 60–69 | 3385 24.8% 28.5% 28.0% 18.7% | 100% | – |
| Adenocarcinoma <40 40–49 50–59 60–69 | 746 21.2% 33.9% 26.7% 18.2% | 100% | – | |||
| Skaznik-Wikiel et al33 2012 | North America | USA 2000–2006 | (All ages) ≥70 | 18 003 ~12% | Not calculable | IIIB, 58.8% |
| Garg et al8 2011 | North America | USA 1988–2005 | Mean age, years 54 49 | 271 289 | – – | IIA1 IIA2 |
| Carmo et al18 2011 | South America | Brazil Rio de Janeiro 1999–2004 | (All ages) <65 ≥65 | 3341 | 70.3% | II (n=1133) 79.9% 20.1% |
<65 ≥65 | III (n=1216) 78.1% 21.9% | |||||
*The Tian 2020 study9 only included patients with locally advanced stages of cervical cancer and squamous cell or adenocarcinoma histology; patients with squamous cell and adenocarcinoma histology were separated for all analyses.